It won approvals to market the drug, called Omacor in Europe (and initially in the US) in several European countries in 2001 after conducting a three and a half year trial in 11,000 subjects;[18] it partnered with other companies like Pierre Fabre in France.[19] In 2004 Pronova licensed the US and Puerto Rican rights to Reliant Therapeutics, the business model of which was in-licensing cardiovascular drugs.[20] In that same year, Reliant and Pronova won FDA approval for the drug[21] and it was launched in the US and Europe in 2005; global sales in 2005 were $144M and by 2008 they were $778M.[22] In 2007 GlaxoSmithKline acquired Reliant for $1.65 billion in cash.[23]